Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 782,650
  • Shares Outstanding, K 35,382
  • Annual Sales, $ 130,190 K
  • Annual Income, $ -24,410 K
  • 60-Month Beta 0.77
  • Price/Sales 5.87
  • Price/Cash Flow N/A
  • Price/Book 12.70
Trade HROW with:

Options Overview Details

View History
  • Implied Volatility 80.49% ( +9.87%)
  • Historical Volatility 49.24%
  • IV Percentile 44%
  • IV Rank 54.83%
  • IV High 133.59% on 04/22/24
  • IV Low 16.04% on 11/30/23
  • Put/Call Vol Ratio 0.46
  • Today's Volume 492
  • Volume Avg (30-Day) 1,359
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 24,108
  • Open Int (30-Day) 23,073

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.25
  • Number of Estimates 1
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -1,150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.87 +31.12%
on 06/17/24
22.30 -0.81%
on 07/05/24
+4.20 (+23.44%)
since 06/05/24
3-Month
9.86 +124.34%
on 04/25/24
22.30 -0.81%
on 07/05/24
+8.61 (+63.73%)
since 04/05/24
52-Week
7.60 +191.05%
on 11/14/23
22.63 -2.25%
on 08/01/23
+3.40 (+18.16%)
since 07/05/23

Most Recent Stories

More News
Stocks Muted as Fed Rate Decision Looms, Micron Earnings on Tap

June S&P 500 E-Mini futures (ESM24) are down -0.07%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.03% this morning as market participants refrained from making big bets ahead of the eagerly awaited...

$SPX : 5,567.19 (+0.54%)
SPY : 554.64 (+0.58%)
$DOWI : 39,375.87 (+0.17%)
DIA : 393.70 (+0.22%)
$IUXX : 20,391.97 (+1.02%)
QQQ : 496.16 (+1.04%)
IP : 42.82 (-1.65%)
JWN : 21.83 (+1.06%)
HD : 334.58 (+0.28%)
SMCI : 846.58 (-0.05%)
AMD : 171.90 (+4.88%)
MRVL : 72.08 (-0.17%)
Why Shares of Harrow Health Are Jumping Wednesday

The company increased guidance, acquired a company, and had a stock sale.

HROW : 22.12 (+2.38%)
Why Shares of Harrow Health Are Slumping Friday

The pharmaceutical company announced first-quarter earnings Thursday afternoon.

HROW : 22.12 (+2.38%)
Harrow to Launch FDA-Approved IHEEZOâ„¢ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of FDA-approved IHEEZO â„¢ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual...

HROW : 22.12 (+2.38%)
Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.

Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for ILEVRO® (nepafenac ophthalmic suspension)...

HROW : 22.12 (+2.38%)
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023, after...

HROW : 22.12 (+2.38%)
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or...

HROW : 22.12 (+2.38%)
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or...

HROW : 22.12 (+2.38%)
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or...

HROW : 22.12 (+2.38%)
HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or...

HROW : 22.12 (+2.38%)

Business Summary

Harrow Inc. is an eyecare pharmaceutical company. It engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products principally for the U.S. market. Harrow Inc., formerly known as Harrow Health Inc., is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 23.23
2nd Resistance Point 22.77
1st Resistance Point 22.44
Last Price 22.12
1st Support Level 21.65
2nd Support Level 21.19
3rd Support Level 20.87

See More

52-Week High 22.63
Last Price 22.12
Fibonacci 61.8% 16.89
Fibonacci 50% 15.11
Fibonacci 38.2% 13.34
52-Week Low 7.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar